Omega-3 Market by Type (DHA, EPA, & ALA), Source (Marine & Plant), Application (Dietary Supplements, Functional Foods & Beverages, Pharmaceuticals, Infant Formulas, and Pet Food & Feed), Form, Manufacturing Technology, and Region – Global Forecast to 2030
The omega-3 market [https://www.marketsandmarkets.com/Market-Reports/omega-3-omega-6-227.html?utm_source=prnewswire.com&utm_medium=paidpr&utm_campaign=omega-3-market] is estimated to be USD 4,362.2 million in 2025 and is projected to reach USD 7,756.4 million by 2030, at a CAGR of 12.2% from 2025 to 2030. Demand for omega-3 is projected to grow significantly as consumers become more aware of its role in supporting cardiovascular, cognitive, eye, and joint health. Unlike several other nutrients, omega-3 fatty acids, such as EPA and DHA, cannot be synthesized efficiently by the human body, resulting in increased reliance on dietary supplements, fortified foods, and pharmaceutical-grade formulations. Omega-3 oils are highly versatile and can be incorporated into capsules, powders, beverages, and functional foods while maintaining stability and efficacy. Fish oil, krill oil, and algal-based omega-3 are the most preferred sources, backed by scientific validation of their safety and effectiveness. The growing popularity among health-conscious consumers, coupled with increasing demand for clean-label and sustainable products, is expected to further strengthen the outlook for the omega-3 market in the coming years.

Image: https://mnmimg.marketsandmarkets.com/Images/omega-3-market-newone-overview.svg

Omega-3 Market Growth Drivers [https://www.prnewswire.com/news-releases/omega-3-market-worth-7-756-4-million-by-2030-exclusive-report-by-marketsandmarkets-302574617.html]:

* Rising Health Awareness: Increasing cases of cardiovascular diseases, cognitive disorders, and inflammatory conditions are fueling the demand for Omega-3 supplements. Consumers are seeking preventive healthcare solutions, positioning Omega-3 as a vital component of daily nutrition.
* Growth in Functional Foods and Nutraceuticals: Food and beverage companies are incorporating Omega-3 into products like fortified dairy, snacks, and beverages, further expanding its market reach.
* Vegetarian and Vegan Alternatives: With more consumers adopting plant-based diets, algae-based Omega-3 products are gaining popularity as sustainable alternatives to fish oil.
* Technological Advancements: Enhanced extraction and purification methods have improved the quality and bioavailability of Omega-3 supplements, boosting consumer trust and adoption.

By type, DHA segment to exhibit fastest growth rate during forecast period

Docosahexaenoic acid (DHA), a polyunsaturated omega-3 fatty acid (PUFA), is widely distributed throughout the body and has emerged as the leading type segment in the omega-3 market. It serves as a significant structural fat present in both the brain and eye, constituting as much as 97% of the total omega-3 fats in the brain and up to 93% in the retina. The main sources of DHA are fish, fish oils, dairy products, and specialty eggs, with marine sources such as salmon and tuna being particularly rich. Farmed salmon contains about 1.24 g of DHA, and wild salmon about 1.22 g of DHA.

Additionally, DHA is a crucial component of cardiac tissue and is also commonly referred to as 22:6(n-3). Direct consumption of DHA is necessary to effectively increase fatty acid levels in the body, and optimal intake is crucial for both infant brain development and normal adult brain function. Epidemiological research further associates healthy DHA intake with a reduced risk of Alzheimer’s disease, as DHA improves communication between nerve cells and membranes by enhancing fluidity. Its critical role in visual and neurological development in infants, coupled with widespread applications in infant nutrition, dietary supplements, and functional foods, has solidified DHA as the dominating segment within the omega-3 market. The growing demand from both developed and emerging economies ensures that DHA continues to hold a substantial market share compared to other omega-3 types, such as EPA and ALA.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=227

By application, infant formulas segment to record highest CAGR during forecast period

The infant formulas segment is anticipated to grow at a significant rate in the omega-3 market due to the rising recognition of DHA’s crucial role in infant brain and eye development. DHA, often referred to as the “brain-building” omega-3, is recommended by leading health authorities such as the World Health Organization (WHO) and the European Food Safety Authority (EFSA) for inclusion in infant nutrition. With an increasing number of working mothers and a higher reliance on formula feeding, demand for fortified infant formulas containing DHA and EPA has surged worldwide. Manufacturers are consistently innovating by introducing premium formulas that mimic the fatty acid composition of human breast milk, further boosting adoption. Regulatory mandates in many regions, such as the EU’s requirement since 2020 for DHA inclusion in all infant formula and follow-on formula products, have led to the European Union (EU) implementing new regulations, effective February 22, 2021, regarding the recommended DHA supplementation in healthy diets. These regulations mandate that all infant formula and follow-on formula available for purchase within the EU must contain a minimum of 20 mg/100 kcal (or 4.8 mg/100 kJ) and a maximum of 50 mg/100 kcal (or 128 mg/100 kJ) of DHA, which is accelerating market growth. In addition, growing consumer preference for organic and clean-label formulas, along with strong demand in emerging economies driven by rising birth rates and improved purchasing power, is expected to fuel the segment’s expansion during the forecast period.

Europe to account for significant share in global omega-3 market

Europe is expected to hold a significant share of the omega-3 market, driven by a robust regulatory framework, high consumer awareness, and a growing preference for preventive healthcare. Additionally, European consumers show a higher inclination toward premium dietary supplements and clean-label products, fostering demand for sustainable fish oil and plant/algal-based omega-3 alternatives. The presence of major global players, continuous research and development initiatives, and widespread adoption of fortified foods and beverages further strengthen Europe’s dominance. Moreover, increasing vegetarian and flexitarian populations in countries such as Germany, the UK, and France are accelerating the demand for algal-derived omega-3, ensuring steady market growth across the region. According to the European Food Safety Authority (EFSA), micronutrients present in omega-3s even benefit eye and brain health, which has led to heavy focus and a surge in consumption among Europeans. Companies such as Pelagia AS (Norway), Corbion (Netherlands), and dsm-firmenich (Netherlands) are the key players that are highly focused on catering to the demand for omega-3-based products in the European region. In 2023, several recent advancements were observed in the omega-3 market within the European region. Corbion (Netherlands) launched a new product, AlgaVia, whereas Pelagia AS (Norway) invested in its production facility to increase the output of the omega-3 concentrates.

The European Society of Cardiology (ESC) has had a significant impact on the omega-3 market in the European region, as its studies emphasize that omega-3 consumption helps decrease the risk of cardiovascular diseases. European omega-3 manufacturers are investing in omega-3 applications, such as dietary supplements, functional food & beverages, and pharmaceuticals. BASF SE (Germany) offers microencapsulated omega-3 powder with more shelf life to cater to the European demand. Furthermore, the rise in consumer awareness has prompted manufacturers to follow and adhere to European regulations, which is projected to drive growth in Europe.

The report profiles key players such as BASF SE (Germany), Cargill, Incorporated (US), dsm-firmenich (Netherlands), ADM (US), Kerry Group plc (Ireland), Aker BioMarine (Norway), Croda International plc (UK), Corbion (Netherlands), Pelagia AS (Norway), KD Pharma Group SA (Switzerland), GC Rieber (Norway), Cooke Aquaculture Inc. (Canada), GOLDEN OMEGA (Chile), Polaris (France), Btsa (Spain), KinOmega Biopharm Inc. (China), Rimfrost AS (Norway), Mara Renewables (Canada), Cellana Inc. (US), AlgaeCytes Limited (UK), and others.

Recent Developments in the Omega-3 Industry [https://www.marketsandmarkets.com/PressReleases/omega-3.asp?utm_source=prnewswire.com&utm_medium=paidpr&utm_campaign=omega-3-market]:

July 2025: Corbion received regulatory approval in China for its algae-based omega-3 solutions, marking a significant milestone in its global expansion strategy. These omega-3 ingredients, derived from microalgae, are designed for use in nutritional supplements, functional foods, and beverages, offering a sustainable and plant-based alternative to traditional fish oil. The approval enables Corbion to enter one of the world’s largest and fastest-growing markets for health and wellness products, reinforcing its commitment to innovation and environmental responsibility in the nutraceutical sector.

April 2025: Epax, a subsidiary of Pelagia AS, launched EPAX Evolve 05, the world’s first commercially available VLC-PUFA (Very Long Chain Polyunsaturated Fatty Acid) product. VLC-PUFAs are a unique class of omega-3 fatty acids with promising benefits for vision, skin health, male fertility, bone density, and muscle strength, especially in the context of healthy aging.

March 2025: Nordmann (Germany) partnered with Aker BioMarine to distribute its marine-based health products, superba krill oil, revervia algae oil, and pl+, across Germany, Austria, and Switzerland. These products are rich in essential omega-3 fatty acids, particularly EPA and DHA, which support heart and liver health. Superba krill oil delivers omega-3s in phospholipid form for better absorption, while revervia offers the highest natural concentration of DHA omega-3 from algae. This strategic collaboration aims to expand access to sustainable, high-quality omega-3 supplements in Central Europe.

Future Outlook

The Omega-3 market is projected to maintain strong growth over the coming years, with increasing opportunities in plant-based alternatives, personalized nutrition, and infant nutrition segments. Companies are expected to invest in research, product innovation, and sustainable sourcing practices to meet consumer demand and strengthen market presence.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=227

Frequently Asked Questions About the Global Omega-3 Market:

Q1. What is the Omega-3 market?

Q2. What is driving the growth of the Omega-3 market?

Q3. Which are the primary sources of Omega-3?

Q4. What are the main applications of Omega-3 fatty acids?

Q5. Which region dominates the Omega-3 market?

Q6. What are the key trends in the Omega-3 market?

Q7. What challenges does the Omega-3 market face?

Q8. What is the market size and growth rate of the Omega-3 market?

Q9. Who are the major players in the Omega-3 market?

Q10. What is the future outlook of the Omega-3 market?

Make an Inquiry: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=227

About MarketsandMarkets Trademark

MarketsandMarkets Trademark has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets Trademark is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore Trademark , which integrates research and provides ecosystem-wide visibility into revenue shifts.

Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=omega3-market-size-growth-drivers-opportunities-latest-trends-top-companies-recent-developments-future-outlook-and-forecast-2030]
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/omega-3-omega-6-227.html

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com

This release was published on openPR.

LOS ANGELES–(BUSINESS WIRE)–$NAGE #Biotech—Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced it has increased its full-year 2025 net sales outlook to 25% to 30% year-over-year growth from 22% to 27%.

“Elevating NAD+ is critical for health, especially as we age, and greater attention to this important area of science is valuable for public health and for Niagen Bioscience,” remarked Rob Fried, CEO of Niagen Bioscience. “We believe the FDA’s latest reversal of previous rulings on the DSHEA drug preclusion rule relating to NMN could serve to increase awareness of the NAD+ precursor market overall and the safety and efficacy of Niagen, in particular. Also, it is important to note that NMN products being sold on the market infringe upon an existing patent portfolio.”

• Niagen is the gold standard NAD+ booster, superior to NAD+ and NMN. Niagen (patented nicotinamide riboside, NR) is rigorously studied, manufactured in the U.S. under the highest quality standards, and backed by multiple safety notifications. Unlike nicotinamide mononucleotide (NMN), which must first be converted into NR before entering human cells, Niagen NR is directly bioavailable, ensuring superior efficacy in raising NAD+ levels in humans. Furthermore, three in four NMN products failed to meet label claims (NutraIngredients USA), with similar quality issues observed internationally (NutraIngredients Asia).
• NMN products on the market infringe on existing intellectual property (IP). Niagen Bioscience’s market surveillance program has tested the NMN, NAD+, and NR products on the market and revealed that every NMN supplement tested infringes upon a robust patent portfolio related to NMN crystallization.
• Growing awareness of the NAD+ supplementation market. Even under the FDA’s previous exclusion, NMN supplements remained widely available, underscoring that regulatory shifts have had minimal impact on Niagen Bioscience’s business due to differentiation in bioavailability, science, quality, and IP.

For more information about Niagen, please visit www.niagenbioscience.com.

About Niagen Bioscience

Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions.

The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.

Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There’s a better way to age.

At the heart of its clinically proven product portfolio is Niagen^® (patented nicotinamide riboside, or NR), the most efficient, well-researched, high-quality, and legal NAD+ booster available. Niagen powers the Company’s consumer supplement, Tru Niagen^®, the number one NAD+ boosting oral supplement in the United States^† (available at www.truniagen.com), and Niagen Plus™, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products (www.niagenplus.com). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription.

Niagen Bioscience’s robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at www.niagenbioscience.com, where copies of press releases, news, and financial information are regularly published.

^† Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 1/1/2024 – 12/31/2024).

Forward Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects,” “anticipates,” “intends,” “estimates,” “plans,” “potential,” “possible,” “probable,” “believes,” “seeks,” “may,” “will,” “should,” “could” or the negative of such terms or other similar expressions, and include statements about 2025 net sales and the impact of recent and potential future regulatory shifts and potential impact of third-party patent rights. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those described. These risks and uncertainties include, but are not limited to, the possibility or outcome of future legal action regarding the FDA’s regulatory shift or regarding enforcement activity by the third-party owner of the patent portfolio related to the crystallization of NMN; the impact of the FDA’s regulatory shift on the Company’s business in light of customer preference and behavior; the scientific, regulatory, and commercial challenges inherent in dietary supplements and healthy-aging research; the acceptance of the Company’s products and educational initiatives; the outcome of ongoing or future clinical studies; protection of intellectual property; competition; and other risks described in Niagen Bioscience’s filings with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Niagen Bioscience undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

Contacts

Niagen Bioscience Media Contact:

Kendall Knysch, Senior Director of Public Relations & Communications

(310) 405-5227

kendall.knysch@niagenbio.com

Niagen Bioscience Investor Relations Contact:

ICR, LLC

Reed Anderson

(646) 277-1260

Stephanie Carrington

(646) 277-1282

niagenir@icrinc.com